Literature DB >> 33086425

Randomized, "head-to-head" studies comparing different SGLT2 inhibitors are definitely needed.

Kazuomi Kario1,2, Noriko Harada1, Satoshi Hoshide1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33086425      PMCID： PMC8029966          DOI： 10.1111/jch.14077

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  21 in total

1.  Combined use of a healthy lifestyle smartphone application and usual primary care counseling to improve arterial stiffness, blood pressure and wave reflections: a Randomized Controlled Trial (EVIDENT II Study).

Authors:  José I Recio-Rodríguez; Emiliano Rodriguez-Sanchez; Carlos Martin-Cantera; Vicente Martinez-Vizcaino; Maria S Arietaleanizbeaskoa; Natividad Gonzalez-Viejo; Marta Menendez-Suarez; Manuel A Gómez-Marcos; Luis Garcia-Ortiz
Journal:  Hypertens Res       Date:  2018-12-26       Impact factor: 3.872

2.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

Review 3.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.

Authors:  Francesco Cosentino; Peter J Grant; Victor Aboyans; Clifford J Bailey; Antonio Ceriello; Victoria Delgado; Massimo Federici; Gerasimos Filippatos; Diederick E Grobbee; Tina Birgitte Hansen; Heikki V Huikuri; Isabelle Johansson; Peter Jüni; Maddalena Lettino; Nikolaus Marx; Linda G Mellbin; Carl J Östgren; Bianca Rocca; Marco Roffi; Naveed Sattar; Petar M Seferović; Miguel Sousa-Uva; Paul Valensi; David C Wheeler
Journal:  Eur Heart J       Date:  2020-01-07       Impact factor: 29.983

4.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

5.  Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Kirk Ways; Mehul Desai; Wayne Shaw; George Capuano; Maria Alba; Joel Jiang; Frank Vercruysse; Gary Meininger; David Matthews
Journal:  Diabetes Care       Date:  2014-12-02       Impact factor: 19.112

6.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

7.  Cardio-ankle vascular index and cardiovascular disease: Systematic review and meta-analysis of prospective and cross-sectional studies.

Authors:  Kunihiro Matsushita; Ning Ding; Esther D Kim; Matthew Budoff; Julio A Chirinos; Bo Fernhall; Naomi M Hamburg; Kazuomi Kario; Toru Miyoshi; Hirofumi Tanaka; Raymond Townsend
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-11-19       Impact factor: 3.738

8.  Sodium-glucose co-transporter-2 inhibitors and arterial stiffness: Class effect or drug effect?

Authors:  Dimitrios Patoulias; Christodoulos Papadopoulos; Alexandra Katsimardou; Maria Toumpourleka; Michael Doumas
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-10-15       Impact factor: 3.738

Review 9.  Recent advances in the management of secondary hypertension: chronic kidney disease.

Authors:  Takahiro Masuda; Daisuke Nagata
Journal:  Hypertens Res       Date:  2020-06-17       Impact factor: 3.872

10.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

Authors:  Milton Packer; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Stuart J Pocock; Peter Carson; James Januzzi; Subodh Verma; Hiroyuki Tsutsui; Martina Brueckmann; Waheed Jamal; Karen Kimura; Janet Schnee; Cordula Zeller; Daniel Cotton; Edimar Bocchi; Michael Böhm; Dong-Ju Choi; Vijay Chopra; Eduardo Chuquiure; Nadia Giannetti; Stefan Janssens; Jian Zhang; Jose R Gonzalez Juanatey; Sanjay Kaul; Hans-Peter Brunner-La Rocca; Bela Merkely; Stephen J Nicholls; Sergio Perrone; Ileana Pina; Piotr Ponikowski; Naveed Sattar; Michele Senni; Marie-France Seronde; Jindrich Spinar; Iain Squire; Stefano Taddei; Christoph Wanner; Faiez Zannad
Journal:  N Engl J Med       Date:  2020-08-28       Impact factor: 176.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.